共 6 条
[1]
Increase in uri-nary leukotriene LTE4levels in acute asthma:correlationwith airflow limitation. Green SA,Malice MP,Tanaka W,et al. Thorax . 2004
[2]
Treatment of asth-ma with drugs modifying the leukotriene pathway. Drazen JM,Israel E,O’Byrne PM. The New England Journal of Medicine . 1999
[3]
Effects of mon-telukast on surrogate inflammatory markers in cortico-steroid-treated patients with asthma. Graeme PC,Daniel KC,Kay H,et al. American Journal of Respiratory and Critical Care Medicine . 2003
[4]
Pharmacologicalmanagement to reduce exacerbations in adults withasthma. Sin DD,Man J,Sharpe H,et al. The Journal of The American Medical Association . 2004
[5]
Circadian char-acteristics of urinary leukotriene E4in healthy subjectsand nocturnal asthmatic patients. Keizo K,Hiroshi T,Shintaro T,et al. Chest . 2001
[6]
The anti-in-flammatory effects of leukotriene-modifying drugs andtheir use in asthma. Salvi SS,Krishna MT,Sampson AP,et al. Chest . 2001